 RADNOR, Pa. , Jan. 5, 2023 PRNewswire -- NRx Pharmaceuticals, Inc. Nasdaq: NRXP NRx Pharmaceuticals, the Company, a clinical-stage biopharmaceutical company, today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates 6th Annual NIF. 